South San Francisco, California, August 19, 2026
IDEAYA Biosciences has entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate IDE892, an investigational MTA-cooperative PRMT5 inhibitor, in combination with Genentech’s GDC-7035 (RG6620), a KRAS G12D inhibitor, in patients with MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC). Under the agreement, Genentech will sponsor the clinical trial, while IDEAYA will provide IDE892. The companies will establish joint governance to oversee the clinical supply collaboration.
Targeting a High-Risk Pancreatic Cancer Population
The collaboration focuses on a molecularly defined group of pancreatic cancer patients whose tumors contain both MTAP deletions and KRAS G12D mutations. According to IDEAYA, these alterations are estimated to co-occur in up to approximately 15% of PDAC patients, creating a potentially important population for precision oncology research. Patients with these molecular characteristics currently have no approved targeted treatment options, highlighting the need for new therapeutic strategies. IDE892 is being evaluated as a potential best-in-class MTA-cooperative PRMT5 inhibitor. PRMT5 is a protein involved in cellular processes that can become particularly important in tumors with specific genetic alterations. IDEAYA is investigating whether targeting PRMT5 in MTAP-deleted tumors can provide a rational approach to selectively disrupt cancer-cell biology. The combination with a KRAS G12D inhibitor is designed to simultaneously target two molecular vulnerabilities associated with the cancer. The companies believe this strategy could potentially produce deeper and more durable responses, although the combination remains investigational and its clinical effectiveness has not yet been established.
IDE892 Enters Expanded Combination Development
IDEAYA is currently evaluating IDE892 in a Phase 1 dose-escalation and expansion trial involving patients with MTAP-deleted solid tumors. The company has also initiated a Phase 1 combination cohort evaluating IDE892 with its proprietary MAT2A inhibitor IDE397 in non-small cell lung cancer and other solid tumors. The newly announced Genentech collaboration adds GDC-7035 (RG6620) as another potential combination partner for IDE892. IDEAYA also plans to initiate a Phase 1 combination cohort with Roche’s RG6505 in MTAP-deleted, RAS-mutant PDAC during the second half of 2026. According to IDEAYA, IDE892 has demonstrated approximately 1,400-fold selective MTA-PRMT5 cooperative binding compared with SAM-PRMT5 cooperative binding in preclinical characterization. The compound is also designed without brain penetration, which the company believes could help maximize its potential therapeutic window. Additional drug-development characteristics are being evaluated to support combinations with targeted oncology agents. These properties are being investigated as part of IDEAYA’s broader strategy to develop precision medicines based on tumor-specific genetic vulnerabilities.
Advertisement
Clinical Collaboration Expands Precision Oncology Strategy
Under the agreement, IDEAYA and Genentech will retain commercial rights to their respective compounds, including potential monotherapy and combination applications. Genentech will sponsor the combination study, while IDEAYA will supply IDE892. The collaboration reflects the increasing use of rational combination therapies in precision oncology, particularly for cancers driven by genetically defined alterations. Pancreatic ductal adenocarcinoma remains an area of significant unmet medical need, and molecularly targeted approaches are being investigated to improve treatment outcomes for patient subsets that can be identified through tumor biomarkers. IDEAYA’s development strategy integrates small-molecule drug discovery, structural biology, bioinformatics and translational biomarker development to identify therapies directed at specific cancer-driving alterations. The company is developing programs focused on synthetic lethality and antibody-drug conjugates across molecularly defined solid tumors. The planned clinical evaluation of IDE892 plus GDC-7035 will provide an opportunity to determine whether simultaneously targeting the PRMT5 pathway and KRAS G12D can deliver meaningful clinical activity in MTAP-deleted, KRAS G12D-mutant PDAC. Because both agents are investigational in this combination, future clinical data will be required to establish the regimen’s safety, tolerability and efficacy.
Source: IDEAYA Biosciences press relese
